Categories
Change Password!
Reset Password!
Nintedanib may improve pulmonary fibrosis in severe pneumonia elicited
by COVID-19.
A study published in the International Journal of Infectious Diseases demonstrated that the administration of nintedanib (an antifibrotic agent that interferes with processes of pulmonary fibrosis) might offer promising benefits for reducing lung injury in adult COVID-19 patients needing mechanical ventilation. This interventional study was carried out to explore the efficacy and safety of nintedanib in people diagnosed with coronavirus infection.
In this single-center study, 28-day mortality following initiation of mechanical ventilation was the major outcome, while the length of mechanical ventilation, the volume of lung impairment, and the occurrence of gastrointestinal side effects and acute hepatic failure were the secondary outcomes. Overall, 30 people infected with SARS-CoV-2 underwent nintedanib treatment. The historical control group incorporated 30 people not receiving nintedanib.
No profound differences were noted
in 28-day mortality between the two groups (23.3% vs 20%). Nintedanib-treated
people exhibited considerably shorter lengths of mechanical ventilation.
Computed tomography volumetry demonstrated that the proportion of
high-attenuation areas were remarkably reduced in the nintedanib-treated people
at liberation from mechanical ventilation (38.7% vs 25.7%). No vital
differences in the adverse events were noted. Thus, nintedanib appears to yield
satisfactory outcomes in SARS-CoV-2-infected people.
International Journal of Infectious Diseases
Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
Yutaka Umemura et al.
Comments (0)